Related Experiment Video
Updated: Sep 18, 2025
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Efficacy of Tucidinostat Pre-emptive Therapy for Peripheral T-cell Lymphoma after Allogeneic Stem Cell
Kohei Takada1, Noriaki Tachi1, Takuto Shonai1
1Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan.
Abstract:
Recently, various molecular targeted therapies have been developed for peripheral T-cell lymphoma (PTCL). However, relapsed/refractory (r/r) PTCL is associated with poor outcomes. Allogeneic stem cell transplantation (allo-SCT) can be effective against r/r PTCL owing to its graft-versus-lymphoma effect. Nevertheless, a posttransplant relapse is common. Although post-transplant preemptive therapy has shown favorable outcomes in leukemia, reports on its use for PTCL are extremely limited. We herein present the case of a patient with refractory PTCL who underwent allo-SCT followed by preemptive therapy with tucidinostat. The patient has maintained complete remission for 2-years. Thus, given its mechanism, tucidinostat may be a viable option for post-transplant therapy.
More Related Videos
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
